Related content

Drug––diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop

By Hinman Lois   Spear Brian   Tsuchihashi Zenta   Kelly James   Bross Peter   Goodsaid Federico   Kalush Francis  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 127-136

Future Medicine

Access to resources Recommend Favorite

19th Annual Drug Information Association (DIA) EuroMeeting: 26-28 March 2007; Vienna, Austria

By Mary Ellen Kitler  

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 4, 2007-01 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite

DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA

By Lesko Lawrence J   Zineh Issam  

Pharmacogenomics, Vol. 11, Iss. 4, 2010-04 ,pp. : 507-512

Future Medicine

Access to resources Recommend Favorite

Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels

By Conrado Daniela J   Rogers Hobart L   Zineh Issam   Pacanowski Michael A  

Pharmacogenomics, Vol. 14, Iss. 2, 2013-01 ,pp. : 215-223

Future Medicine

Access to resources Recommend Favorite

4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

By Nolan David   Christiansen Frank  

Expert Opinion on Drug Safety, Vol. 2, Iss. 1, 2003-01 ,pp. : 95-101

Informa Healthcare

Access to resources Recommend Favorite